Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Apr 24;96(10):1560–1568. doi: 10.1038/sj.bjc.6603766

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Versican modulates glioma migration mediated by TGF-β2. (A) The expression of versican at protein level was detected by Western blotting probed with versican V0/V1 antibody. Migrating cells and non-migrating spheroids were analysed separately. β-Actin was used as loading control. Migrating cells express remarkably higher levels of versican V1 than non-migrating cells. Densitometric values in percentages in the upper panel show almost 100% increase of versican expression in migrating cells compared to non-migrating spheroid cells. (B) Effect of versican on glioma migration mediated by TGF-β2 was analysed in spheroid assays as described in methods. The spheroids treated with TGF-β2 protein were also exposed to versican V0/V1 antibody (20 μg ml⁻¹). We also analysed spheroids exposed to versican V0/V1 antibody without TGF-β2. The TGF-β2-treated cells show significantly higher migration rates (^**P<0.01). Versican V0/V1 antibody was able to decrease migration, both with or without exogenous TGF-β2 protein compared to untreated control and control IgG (^**P<0.01). Results are shown with the mean±standard deviation of migration distance in percentages detected from two experiments; six spheroids were used for each experimental condition. Untreated (control) are expressed as 100%. Images taken at day 3 are shown in the upper panel. The scale bar is 200 μm. P-values (untreated vs treated cells) are written in the columns for each experimental condition.